The acquisition centers on TachoSil, a hemostat and sealant patch with two decades of clinical use across cardiovascular, neuro, hepatic, and thoracic specialties. Backed by more than 540 clinical trial publications, the product remains a staple for surgeons seeking rapid bleeding control in high-stakes environments. Upon completion of the transaction, Sheri McCoy, former Chair of Johnson & Johnson’s Surgical Care Group, will join as Board Chair of the newly independent company.

Operating from a specialized manufacturing facility in Linz, Austria, the business employs roughly 400 people. EQT plans to leverage this base to accelerate commercial growth, particularly within the United States. The strategy includes expanding clinical indications, increasing global market penetration, and potentially building a broader biosurgery platform through strategic acquisitions. Thierry Leclercq will continue to lead the organization, working alongside EQT to scale operations and innovation. Piper Sandler served as financial advisor for the transaction, with Latham & Watkins providing legal counsel.